

# Drug Coverage Decision for B.C. PharmaCare

**About PharmaCare** B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	fluticasone propionate
<b>Brand Name</b>	Aermony Respiclick™
<b>Dosage Forms</b>	55mcg/actuation, 113 mcg/actuation, and 232 mcg/actuation dry powder for inhalation
<b>Manufacturer</b>	Teva Canada Innovation
<b>Submission Type</b>	<b>New Submission</b>
<b>Use Reviewed</b>	For the treatment of asthma in patients aged 12 years and older
<b>Common Drug Review (CDR)</b>	CDR recommended: <b>to Reimburse with clinical criteria and/or conditions</b> . Visit the CDR website for more details: <a href="http://www.cadth.ca/sites/default/files/cdr/complete/SR0539%20Aermony%20RespiClick%20-%20CDEC%20Final%20Recommendation%20for%20posting%20December%2021%2C%202018.pdf">www.cadth.ca/sites/default/files/cdr/complete/SR0539%20Aermony%20RespiClick%20-%20CDEC%20Final%20Recommendation%20for%20posting%20December%2021%2C%202018.pdf</a>
<b>Provincial Review</b>	The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened Aermony Respiclick on December 4, 2017. The DBC advised that, because Aermony Respiclick is similar to some of the other products used for the treatment of asthma, the Ministry may accept the CDEC's recommendation for Aermony Respiclick.
<b>Drug Coverage Decision</b>	<b>Non-Benefit</b>
<b>Date</b>	February 11, 2020
<b>Reasons</b>	<ul style="list-style-type: none"> <li>Teva Canada Innovation confirmed that they are unable to bring Aermony Respiclick to the Canadian market at sufficient quantities at this time.</li> </ul>
<b>Other Information</b>	None

### **The Drug Review Process in B.C.**

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.